查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2046724

藥品監管管理系統市場－全球產業規模、佔有率、趨勢、機會、預測：按組件、部署方式、最終用戶、地區和競爭格局分類，2021-2031年

Pharma Regulatory Management Systems Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Component, By Deployment, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球藥品監管管理系統市場預計將從 2025 年的 102.9 億美元大幅成長至 2031 年的 182.7 億美元，複合年成長率為 10.04%。

這些系統是集中式軟體平台，旨在促進全球衛生監管機構對監管內容的規劃、追蹤和提交。這使生命科學公司能夠持續遵守不斷變化的標準，並在整個研發生命週期中管理大量的產品註冊資料。推動該市場發展的關鍵因素包括：新治療方法快速上市的需求日益成長，以及全球監管要求的日益複雜化，這些要求需要準確的數據和強力的跨部門合作。

市場概覽
預測期 2027-2031
市場規模：2025年 102.9億美元
市場規模：2031年 182.7億美元
複合年成長率：2026-2031年 10.04%
成長最快的細分市場 現場
最大的市場 北美洲

然而，該市場面臨許多挑戰，包括系統實施的高昂成本以及將新平台與現有傳統基礎設施整合的難度。這些財務和營運負擔往往會限制部門能力，並阻礙更廣泛的數位轉型工作。例如，監管事務專業人員協會 (RAPS) 2024 年的一份報告發現，57% 的製藥公司缺乏足夠的資源來實現其監管目標。因此，儘管對自動化的需求很高，但預算限制和資源短缺是可能減緩企業採用這些關鍵管理系統的主要障礙。

市場促進因素

推動市場發展的關鍵因素之一是監管資訊管理解決方案向雲端快速轉型。企業正在摒棄分散的傳統工具，轉而採用整合化、數據驅動的平台。這項轉變對於維護資料完整性、促進全球研發團隊之間的順暢協作至關重要，尤其是在企業對其合規基礎設施進行現代化改造之際。近期產業數據凸顯了這項現代化進程的顯著程度。例如，Veeva Systems報告稱，截至2025年3月會計年度末，其研發解決方案客戶數量已達1,125家，顯示整個產業正在迅速向雲端架構轉型。此外，老字型大小企業也越來越依賴這些平台來滿足其不斷成長的營運需求。 ArisGlobal在2025年7月指出，其現有客戶中有31%在上半年擴大了平台的使用範圍。這既凸顯了市場成長，也反映了對全面法律規範的策略需求。

同時，生命科學市場和臨床試驗的全球化也是一股重要的驅動力，迫使企業部署能夠適應不同地區監管要求和電子申報標準的系統。隨著製藥研發公司將業務拓展至新興經濟體進行臨床試驗和產品上市，它們需要高度適應性的基礎設施來遵守複雜的當地法規。這種全球擴張策略催生了對在地化且一體化的監管合規能力的巨大需求。例如，根據ArisGlobal的研究，到2025年7月，亞太地區運作的監管和安全系統數量將年增233%。這一顯著成長表明，全球擴張正在直接推動對健全的監管管理系統的投資，以確保不同地區合規性的一致性。

市場挑戰

全球藥品監管管理系統市場成長面臨的最大障礙是財務和營運壓力，主要源自於資源限制和過重的工作量，嚴重考驗著各部門的能力。儘管自動化需求毋庸置疑，但在複雜的監管環境下，維持合規所需的龐大工作量和沈重的財務負擔往往會延緩此類集中式系統的實施。當監管回應團隊不堪重負時，他們便缺乏管理實施新數位基礎設施這一龐大且成本高昂的過程所需的能力和戰略重點。

監管核准與實際上市之間的時間差不斷擴大，這從量化角度反映了監管部門的負擔，而這個過程本身也消耗了大量的部門資源。歐洲製藥工業協會聯合會（EFPIA）在2025年發布的報告顯示，歐洲新藥從監管核准到病患用藥的平均時間為578天。如此漫長的核准週期給監管響應團隊帶來了巨大的營運壓力，迫使他們將有限的資金和人力資源用於應對這些延誤以及處理各國不同的報銷制度，而不是投資或實施新的管理軟體。因此，維持現有營運和應對延長的上市週期這一緊迫挑戰，阻礙了數位轉型工作，而數位轉型最終本可以簡化這些流程。

市場趨勢

一個顯著的市場趨勢是，人們正從僅僅考慮人工智慧 (AI) 和機器學習轉向積極採用這些技術來自動化監管工作，以應對日益成長的數據量。這項進步將使團隊能夠自動化準備申請文件等任務，使專家能夠專注於更具策略性的決策。業界對這些技術的應用表現出極大的熱情，他們將這些技術視為增強人類能力的工具，而非取代人類能力的手段。例如，根據《監管報告員》(Regulatory Rapporteur) 2025 年 3 月刊發表的報導，76% 的負責人現在認為人工智慧是能夠增強其工作的助手，這反映出員工對數位化協作的看法發生了重大轉變。

另一個重要趨勢是實施符合 ISO IDMP 和 SPOR 資料標準。這透過強制轉向結構化資料模型，重新定義了企業交換產品資訊的方式。這種標準化確保了與 EMA SPOR 等監管資料庫的兼容性，是加強藥物安全檢測和在現有數據挑戰下保持數據一致性的關鍵一步。隨著世界各地的監管機構強制執行這些要求，進展顯而易見。根據監管事務專業人員協會 (RAPS) 2025 年 2 月發表的報導，核准上市核准申請中 70% 的物質已映射到 IDMP 標準，這表明合規基礎設施的成熟度達到了一個重要的里程碑。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球藥品監理管理系統市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 按組件（服務、解決方案）
    • 部署類型（雲端、本機部署）
    • 依最終用戶分類（政府機構、醫院/護理機構、製藥/生技公司）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美藥品監理管理系統市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲藥品監理管理系統市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區藥品監理管理系統市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲藥品監管和控制系統市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲藥品監理管理系統市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章 全球藥品監理管理系統市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Instem PLC
  • NNIT A/S
  • Amplexor USA Inc
  • MasterControl Inc
  • Charles River Laboratories International Inc.
  • Parexel International Corporation
  • IQVIA Inc.
  • ICON Inc.
  • Pharmalex GmbH

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 18804

The global market for Pharma Regulatory Management Systems is projected to expand significantly, rising from USD 10.29 Billion in 2025 to USD 18.27 Billion by 2031, demonstrating a Compound Annual Growth Rate (CAGR) of 10.04%. These systems are centralized software platforms that facilitate the planning, tracking, and submission of regulatory content to health authorities globally. They empower life sciences firms to maintain compliance with evolving standards and manage extensive product registration data throughout the entire development lifecycle. Key drivers for this market include the urgent need to expedite new therapies to market and the increasing complexity of global regulatory requirements, which necessitate precise data and robust cross-functional collaboration.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 10.29 Billion
Market Size 2031USD 18.27 Billion
CAGR 2026-203110.04%
Fastest Growing SegmentOn-Premises
Largest MarketNorth America

However, this market faces notable challenges, including the substantial costs associated with implementing these systems and the difficulty of integrating new platforms with existing legacy infrastructure. Such financial and operational strains often limit departmental capacity and hinder broader digital transformation efforts. For example, in 2024, the Regulatory Affairs Professionals Society reported that 57% of pharmaceutical organizations lacked sufficient resources to meet their regulatory objectives. Therefore, despite a strong demand for automation, budget limitations and resource shortages pose considerable obstacles that may defer the widespread adoption of these crucial management systems across enterprises.

Market Driver

A primary market driver is the swift shift towards cloud-based Regulatory Information Management solutions, as businesses move away from fragmented legacy tools to adopt unified, data-driven platforms. This transition is vital for maintaining data integrity and fostering smooth collaboration among global R&D teams, especially as companies strive to modernize their compliance infrastructure. The extent of this modernization is highlighted by recent industry data; for instance, Veeva Systems reported 1,125 R&D Solutions customers at the close of its fiscal year in March 2025, indicating a rapid industry-wide migration to cloud architectures. Furthermore, established enterprises are increasingly relying on these platforms to manage growing operational demands, with ArisGlobal noting in July 2025 that 31% of its existing customers expanded their platform usage in the first half of the year, underscoring both market growth and the strategic necessity of thorough regulatory oversight.

Concurrently, the globalization of life sciences markets and clinical trials acts as another significant driver, pushing companies to implement systems capable of handling diverse regional mandates and electronic submission standards. As pharmaceutical developers expand into emerging economies for clinical studies and product launches, they require adaptable infrastructure to navigate intricate local regulations. This global expansion strategy is creating substantial demand for regulatory capabilities that are both localized and integrated. For example, ArisGlobal observed a 233% year-over-year increase in regulatory and safety system go-lives within the Asia-Pacific region by July 2025. This marked increase demonstrates how global expansion initiatives are directly stimulating investment in robust regulatory management systems to ensure consistent compliance across different regions.

Market Challenge

A significant challenge impeding the growth of the Global Pharma Regulatory Management Systems Market arises from financial and operational pressures that severely test departmental capacities, primarily due to resource constraints and heavy operational loads. Although the need for automation is undeniable, the implementation of these centralized systems is often delayed by the magnitude of current workloads and the financial burden associated with maintaining compliance in a complex regulatory landscape. When regulatory teams are burdened by daily operational demands, they lack the capacity and strategic attention necessary to manage the extensive and expensive process of deploying new digital infrastructure.

This strain is quantitatively demonstrated by the increasing time lag between regulatory approval and actual market availability, a process that consumes considerable departmental resources. As reported by the European Federation of Pharmaceutical Industries and Associations (EFPIA) in 2025, the average duration from regulatory approval to patient access for new medicines across Europe extended to 578 days. This prolonged timeline imposes immense operational stress on regulatory affairs teams, compelling them to allocate their limited financial and human capital to managing these delays and navigating varied national reimbursement frameworks, rather than investing in and implementing new management software. Consequently, the immediate imperative of maintaining existing operations and managing these extended access cycles obstructs the digital transformation initiatives that could ultimately streamline these very processes.

Market Trends

A notable market trend is the move from exploring to actively deploying Artificial Intelligence and Machine Learning for regulatory automation, aiming to manage the increasing volumes of data. This advancement allows teams to automate tasks such as dossier creation, thereby enabling experts to focus on more strategic decisions. The industry shows strong readiness to adopt these technologies, viewing them as tools that enhance human capabilities rather than replacing them. For instance, an article in the Regulatory Rapporteur in March 2025 on 'AI adoption readiness' indicated that 76% of regulatory professionals now perceive AI as an assistant that can improve their roles, reflecting a significant change in how the workforce views digital collaboration.

Another key trend involves the implementation of ISO IDMP and SPOR Data Standards Compliance, which is redefining how companies exchange product information by mandating a shift to structured data models. This harmonization ensures compatibility with regulatory databases, such as the EMA's SPOR, a crucial step for enhancing pharmacovigilance and maintaining data consistency, despite existing challenges with legacy data. Measurable progress is evident as regulatory bodies worldwide enforce these requirements. According to the Regulatory Affairs Professionals Society in February 2025, their article 'Regulators report on progress toward implementing IDMP' highlighted that 70% of substances approved in marketing applications have already been mapped to IDMP standards, indicating a significant milestone in compliance infrastructure maturity.

Key Market Players

  • Instem PLC
  • NNIT A/S
  • Amplexor USA Inc
  • MasterControl Inc
  • Charles River Laboratories International Inc.
  • Parexel International Corporation
  • IQVIA Inc.
  • ICON Inc.
  • Pharmalex GmbH

Report Scope

In this report, the Global Pharma Regulatory Management Systems Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pharma Regulatory Management Systems Market, By Component

  • Services
  • Solutions

Pharma Regulatory Management Systems Market, By Deployment

  • On-Cloud
  • On-Premises

Pharma Regulatory Management Systems Market, By End User

  • Government Agencies
  • Hospitals & Care Providers
  • Pharmaceutical & Biotechnology Companies

Pharma Regulatory Management Systems Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pharma Regulatory Management Systems Market.

Available Customizations:

Global Pharma Regulatory Management Systems Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Pharma Regulatory Management Systems Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Component (Services, Solutions)
    • 5.2.2. By Deployment (On-Cloud, On-Premises)
    • 5.2.3. By End User (Government Agencies, Hospitals & Care Providers, Pharmaceutical & Biotechnology Companies)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Pharma Regulatory Management Systems Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Component
    • 6.2.2. By Deployment
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Pharma Regulatory Management Systems Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Component
        • 6.3.1.2.2. By Deployment
        • 6.3.1.2.3. By End User
    • 6.3.2. Canada Pharma Regulatory Management Systems Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Component
        • 6.3.2.2.2. By Deployment
        • 6.3.2.2.3. By End User
    • 6.3.3. Mexico Pharma Regulatory Management Systems Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Component
        • 6.3.3.2.2. By Deployment
        • 6.3.3.2.3. By End User

7. Europe Pharma Regulatory Management Systems Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Component
    • 7.2.2. By Deployment
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Pharma Regulatory Management Systems Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Component
        • 7.3.1.2.2. By Deployment
        • 7.3.1.2.3. By End User
    • 7.3.2. France Pharma Regulatory Management Systems Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Component
        • 7.3.2.2.2. By Deployment
        • 7.3.2.2.3. By End User
    • 7.3.3. United Kingdom Pharma Regulatory Management Systems Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Component
        • 7.3.3.2.2. By Deployment
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy Pharma Regulatory Management Systems Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Component
        • 7.3.4.2.2. By Deployment
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Pharma Regulatory Management Systems Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Component
        • 7.3.5.2.2. By Deployment
        • 7.3.5.2.3. By End User

8. Asia Pacific Pharma Regulatory Management Systems Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Component
    • 8.2.2. By Deployment
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Pharma Regulatory Management Systems Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Component
        • 8.3.1.2.2. By Deployment
        • 8.3.1.2.3. By End User
    • 8.3.2. India Pharma Regulatory Management Systems Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Component
        • 8.3.2.2.2. By Deployment
        • 8.3.2.2.3. By End User
    • 8.3.3. Japan Pharma Regulatory Management Systems Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Component
        • 8.3.3.2.2. By Deployment
        • 8.3.3.2.3. By End User
    • 8.3.4. South Korea Pharma Regulatory Management Systems Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Component
        • 8.3.4.2.2. By Deployment
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Pharma Regulatory Management Systems Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Component
        • 8.3.5.2.2. By Deployment
        • 8.3.5.2.3. By End User

9. Middle East & Africa Pharma Regulatory Management Systems Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Component
    • 9.2.2. By Deployment
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Pharma Regulatory Management Systems Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Component
        • 9.3.1.2.2. By Deployment
        • 9.3.1.2.3. By End User
    • 9.3.2. UAE Pharma Regulatory Management Systems Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Component
        • 9.3.2.2.2. By Deployment
        • 9.3.2.2.3. By End User
    • 9.3.3. South Africa Pharma Regulatory Management Systems Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Component
        • 9.3.3.2.2. By Deployment
        • 9.3.3.2.3. By End User

10. South America Pharma Regulatory Management Systems Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Component
    • 10.2.2. By Deployment
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Pharma Regulatory Management Systems Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Component
        • 10.3.1.2.2. By Deployment
        • 10.3.1.2.3. By End User
    • 10.3.2. Colombia Pharma Regulatory Management Systems Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Component
        • 10.3.2.2.2. By Deployment
        • 10.3.2.2.3. By End User
    • 10.3.3. Argentina Pharma Regulatory Management Systems Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Component
        • 10.3.3.2.2. By Deployment
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Pharma Regulatory Management Systems Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Instem PLC
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. NNIT A/S
  • 15.3. Amplexor USA Inc
  • 15.4. MasterControl Inc
  • 15.5. Charles River Laboratories International Inc.
  • 15.6. Parexel International Corporation
  • 15.7. IQVIA Inc.
  • 15.8. ICON Inc.
  • 15.9. Pharmalex GmbH

16. Strategic Recommendations

17. About Us & Disclaimer